Abstract
Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. Objective of this study was to correlate these measures. Among the 256 enrolled patients, 11 (4.3%) showed a significant inhibition of the IFNbeta activity in vitro, but no measurable BAbs. As a whole, in vivo bioactivity was inhibited in 9/11 (82%) of these patients. A minority of IFNbeta treated patients have a non-antibody mediated neutralising activity, which competitively inhibits the bioactivity both in vitro and in vivo.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies / therapeutic use*
-
Case-Control Studies
-
Enzyme-Linked Immunosorbent Assay / methods
-
Female
-
Follow-Up Studies
-
GTP-Binding Proteins / genetics
-
GTP-Binding Proteins / metabolism
-
Gene Expression / drug effects
-
Humans
-
Immunoprecipitation
-
In Vitro Techniques
-
Interferon-beta / immunology*
-
Interferon-beta / therapeutic use*
-
Male
-
Multiple Sclerosis / immunology*
-
Multiple Sclerosis / therapy
-
Myxovirus Resistance Proteins
-
Neutralization Tests
-
Receptors, Interferon / metabolism
-
Retrospective Studies
Substances
-
Antibodies
-
Myxovirus Resistance Proteins
-
Receptors, Interferon
-
Interferon-beta
-
GTP-Binding Proteins